2006
DOI: 10.1111/j.1538-7836.2006.02195.x
|View full text |Cite
|
Sign up to set email alerts
|

von Willebrand factor activates endothelial nitric oxide synthase in blood platelets by a glycoprotein Ib‐dependent mechanism

Abstract: To cite this article: Riba R, Oberprieler NG, Roberts W, Naseem KM. von Willebrand factor activates endothelial nitric oxide synthase in blood platelets by a glycoprotein Ib-dependent mechanism. J Thromb Haemost 2006; 4: 2636-44.Summary. Background: The molecular regulation of endothelial nitric oxide synthase (eNOS) in blood platelets and the signalling events induced by platelet-derived NO are poorly defined. In particular, the ability of von Willebrand factor (VWF) to stimulate cyclic guanosine monophosphat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
33
2

Year Published

2007
2007
2017
2017

Publication Types

Select...
4
4
1

Relationship

0
9

Authors

Journals

citations
Cited by 40 publications
(38 citation statements)
references
References 34 publications
3
33
2
Order By: Relevance
“…One report does suggest that vWF stimulates platelet-mediated production of nitric oxide, which could decrease pulmonary vascular resistance, pulmonary artery pressure, and RV workload 22 ; however, this report conflicts with others that suggest increased vWF is associated with decreased nitric oxide. 23 Alternatively, because our study was cross-sectional, reverse causation could explain the findings.…”
Section: Discussioncontrasting
confidence: 67%
“…One report does suggest that vWF stimulates platelet-mediated production of nitric oxide, which could decrease pulmonary vascular resistance, pulmonary artery pressure, and RV workload 22 ; however, this report conflicts with others that suggest increased vWF is associated with decreased nitric oxide. 23 Alternatively, because our study was cross-sectional, reverse causation could explain the findings.…”
Section: Discussioncontrasting
confidence: 67%
“…39,40 Other endogenous factors that may be involved in the regulation of platelet NOS3 activity include von Willebrand factor (vWF) and glucose. 41,42 vWF activates platelet NOS3 and increases intraplatelet cGMP, as well as inducing phosphorylation of vasodilator-stimulated phosphoprotein (VASP, a cGMP substrate). It does so by acting through its receptor GPIb, and in a Ca 2ϩ -sensitive manner which requires the participation of PI3-K and phospholipase C; it also involves the generation of ADP and TxA 2 , because vWF-induced cGMP production is blocked by apyrase and indomethacin.…”
Section: The L-arginine-no Pathway In Plateletsmentioning
confidence: 99%
“…It does so by acting through its receptor GPIb, and in a Ca 2ϩ -sensitive manner which requires the participation of PI3-K and phospholipase C; it also involves the generation of ADP and TxA 2 , because vWF-induced cGMP production is blocked by apyrase and indomethacin. 41 High glucose activates NOS3 in resting platelets by an osmotic mechanism that probably involves the ␤ isoform of PKC, activation of which causes an increase in intraplatelet Ca 2ϩ . 42,43 Although the importance of phosphorylation of NOS3 in the regulation of its activity in platelets is well accepted, only 1 phosphorylation site, namely that on Ser 1177 , is currently established as being of importance in this regard.…”
Section: The L-arginine-no Pathway In Plateletsmentioning
confidence: 99%
“…15,19,20 In addition, vWF binding to GPIb-IX has been shown to induce NO synthesis and cGMP elevation. 15,21 Thus, it is important to understand the upstream signaling mechanisms that activate the NOcGMP-p38-ERK pathway and the role of this pathway in early GPIb-IX signaling.…”
Section: Introductionmentioning
confidence: 99%